Gland Pharma- Generic Injectables

Stock Analysis & Valuation
40

Does management highlighted any reason on why Q2 & Q3 PAT are lower than Q1 and no growth Q3 compared to Q2.

With this rate, they can’t even match PAT of FY20

2 Likes